In this study we evaluated myeloproliferative neoplasm patients' serologic and T-cell responses 1 month after SARS-CoV-2 vaccination. While response rates were overall high, subtle deficiencies in T-cell responses likely indicate some impaired cellular immunity that requires further investigation.
In this study we evaluated thrombosis and bleeding outcomes in myeloproliferative neoplasm (MPN) patients treated with direct oral anticoagulants (DOACs). We found an unexpected high cumulative incidence of bleeding, emphasizing the need for continued rigorous evaluation of DOACs in MPNs.